HX575 recombinant human erythropoietin alfa; ERYPO
Проводит Сандоз АГ
Страница компанииRandomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00701714/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование прекращено досрочно, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 337 чел. во всех странах исследования.
- Центров в реестре: 24 в 13 городах. Список — ниже на странице.
- Плановая дата окончания (01.2010) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 28
Критерии включения
- Known chronic renal insufficiency of at least 4 weeks duration; CKD stage at least 3 or higher
- Male and female patients, age: >=18
- Patients who are naïve to ESA treatment or previously ESA treated after 3 months of ESA-free period (i.v. or s.c.)
- Patients with symptomatic anemia, defined as Hb level below 11.0 g/dL and not lower than or equal to 7.5 g/dL on at least 2 visits during the screening period
- Adequate iron status, serum ferritin >= 100 µg/L or transferrin saturation >= 20%
- Ability to follow study instructions and likely to complete all required visits and compliant with subcutaneous administration
- Written informed consent of the patient.
Критерии невключения
- Anemia of non-renal causes
- Therapy with immunosuppressants (other than corticosteroids for chronic treatment) within 3 months before screening and during the study for patients with renal allograft in place or other chronic conditions (e.g. lupus erythematosus, rheumatic arthritis)
- Patients previously treated with chronic dialysis within the last 6 months (exception: one session of acute dialysis)
- Patients with acute deterioration of renal function during the screening phase according to the investigator's judgment
- Patients receiving any RBC/whole blood transfusion during the screening period
- Primary hematological disorder (e.g. myeloma, myelodysplastic syndrome, sickle cell anemia, hematological malignancy, hemolytic anemia)
- Evidence of uncontrolled diabetes mellitus (HbA1c > 10 % at visit -2)
- Evidence of severe hepatic dysfunction (e.g. ALT and/or AST above 2x upper limit of normal range; or gamma-GT above 3x upper limit of normal range)
- Clinical evidence of current uncontrolled or symptomatic hyperparathyroidism, defined as parathyroid hormone > 500 ng/L at visit -2.
- Uncontrolled hypertension, defined as a systolic blood pressure of >= 160 mmHg and a diastolic blood pressure measurement >= 100 mmHg (average of two values with at least one day between measurements)
- Congestive heart failure and/or angina pectoris \[New York Heart Association (NYHA) class III and IV\]
- History of stroke or myocardial infarction during the last 6 months prior to visit -2
- Ongoing treatment with phenprocoumon or other cumarin derivates
- Thrombocytopenia (platelet count <100.000/µL) or leucopenia (white blood cell count < 2.000/µL)
- Gastrointestinal bleeding within the last 6 months prior to visit -2 or hemolysis
- Evidence of acute or chronic infection by a C-reactive protein value of > 30 mg/L
- Suspicion or known PRCA (pure red cell aplasia)
- Previously diagnosed HIV or acute hepatitis infection
- History of epilepsy or epileptic seizures or treatment for epilepsy within the past 6 months prior to screening
- Planned major surgery (with expected high blood loss) during the next 3 months or major surgery within the previous 3 months (except laser photocoagulation, access surgery)
- Clinical evidence of active malignant diseases within the last 5 years (except non-melanoma skin cancer)
- Pregnancy, breastfeeding women or women not using a highly effective birth control method (e.g. implants, injectables, combined oral contraceptives, IUD, sexual abstinence, vasectomised partner)
- Known history of severe drug related allergies (e.g. anaphylactic shock)
- Known allergy to one of the ingredients of the test product or hypersensitivity to mammalian-derived products
- Known or suspicion of any non-compliance with respect to subcutaneous treatment
- Simultaneous participation in another clinical study or participation in a study in the month preceding visit-2 or previously randomized in this study
- Participation in another ESA study in the 3 months preceding visit -2
- Any other condition which at the investigator's discretion may put the patient at risk or which may confound the study results.
Источник: ClinicalTrials.gov, NCT00701714 · запись обновлена в реестре 5 февраля 2018.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 1
- Change in Hemoglobin Level — 13 weeks
- Weekly Epoetin Dose — weeks 11-13
Цель исследования
This is a randomized, controlled, double-blind, multicenter multinational safety study involving about 300 predialysis patients aged 18 years or above suffering from anemia.
Symptomatic anemia will be corrected by s.c. application of EPO HEXAL or ERYPO® in order to achieve a hemoglobin target range of 10.0 -12.0 g/dL.
Где проходит
24 центра в 13 городах- Federal State Institution «National Medical Surgery center named after NI Pirogov of Federal Agency of Health Care and Social Development»
- Russian University of Peoples Frienship (clinical base: City clinical hospital #53)
- State Educational Institution of Higher Professional Education «Moscow State University of Medicine and dentistry of Federal Agency of health Care and Social Development», City Clinical Hospital #23
- State Health Care Institution City Clinical Hospital named after SP Botkin
- Saint- Petersburg State Mtchnikov's Medical Academy
- Saint-Petersburg I.I. Dzhanelidze Research Institute of Emergency Medicine
- St. Petersburg State Healthcare Institution «City Outpatient Clinic #17»
- State Educational Institution of Higher Professional Education «St. Petersburg State Medical Academy for Postgraduate studies of Roszdrav»
- State Educational Institution of Higher Professional Education «St. Petersburg State Medical Institute named after IP Pavlov of Roszdrav»
- State Institute St. Petersburg
- СПб ГБУЗ «Городская Мариинская больница»
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00701714 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.